ShEEP request for a Helios CyTOF MS

摘要 贝德福德退伍军人医院申请资金收购Helios CyTOF飞行时间 原子质谱仪(MS)，由Fluidigm制造。目前，我们医院多发性硬化症 实验室配备了Q Exactive杂交Orbitrap MS，Quantiva三重四极MS， 和QSTAR MS/MS系统。新的Helios CyTOF MS将结合细胞细胞仪， 电感耦合等离子体、飞行时间质谱仪组成单一仪器。这是完全不同的 来自现有的MS仪器。随着Helios CyTOF MS的增加，我们将扩展核心 贝德福德退伍军人医院研究和开发计划的生物标志物检测能力。 该仪器将在支持的多学科临床研究中发挥重要作用 VA为我们提供了无与伦比的表型和功能分析细胞的能力 从正常状态和疾病状态。Helios CyTOF MS将用于多个VA资助 由夏博士、斯坦博士和汉伦博士(主要用户)以及其他负责人指导的研究 贝德福德退伍军人医院的调查人员(未成年用户)(Moo，Morin，Wells，Semenov博士)， 波士顿退伍军人健康系统(DRIVER)和拉斯穆森博士(Rasmusson)以及哥伦比亚退伍军人医院(Gu博士)。 Helios CyTOF MS将被用于分析大量的生物样本进行研究 与中枢神经系统紊乱有关。具体地说，它将被用来描述诱导 多能干细胞(IPSC)，并了解和促进从 外周血单个核细胞(PBMC)转化为IPSC。对治疗的反应将被预测 (目标1)。Helios CyTOF将用于帮助建立受试者的外周生物标记物 患有慢性创伤性脑病或路易体痴呆，并与 神经病理和近红外(NIR)光谱分析(AIM 2)。单细胞 Helios CyTOF获得的蛋白质组学将与血液中的代谢组学和脂质组学相结合 来自阿尔茨海默病(AD)患者的样本(目标3)。最后，多项生物标记物研究 由VA和NIH支持的单细胞蛋白质组图谱将得到Helios的证实 CyTOF(Aim 4)。

Abstract The Bedford VA hospital requests for fund to acquire the Helios CyTOF time-of-flight atomic Mass Spectrometer (MS), manufactured by Fluidigm. Currently, our hospital MS laboratory is equipped with a Q Exactive hybrid Orbitrap MS, a Quantiva Triple Quadrupole MS, and a QSTAR MS/MS system. The new Helios CyTOF MS will combine cell cytometer, inductively coupled plasma, time-of-flight MS into a single instrument. It is completely different from existing MS instruments. With the addition of Helios CyTOF MS, we will expand core biomarker detection capability at the Bedford VA Hospital Research and Development program. This instrument will play an important role in multi-disciplinary clinical studies that are supported by VA, providing us with an unparalleled ability to phenotypically and functionally profile cells from normal and diseased states. The Helios CyTOF MS will be used for multiple VA funded studies directed by Drs. Xia, Stein and Hanlon (major users), along with other principal investigators (minor users) at the Bedford VA Hospital (Drs. Moo, Morin, Wells, Semenov), Boston VA Health System (Drs. Driver and Rasmusson), and Columbia VA Hospital (Dr. Gu). The Helios CyTOF MS will be used to analyze a large variety of biological samples for studies related to central nervous system disorders. Specifically, it will be used to characterize induced pluripotent stem cells (iPSC) and to understand and facilitate the reprogramming process from peripheral blood mononuclear cells (PBMC) to iPSC. Response to therapeutics will be predicted (Aim 1). The Helios CyTOF will be used to help establish peripheral biomarkers from subjects with chronic traumatic encephalopathy or Lewy Body Dementia and correlate to neuropathological and Near Infrared (NIR) spectra based analysis (Aim 2). Single-cell proteomics obtained by Helios CyTOF will be profiled with metabolomics and lipidomics in blood samples from Alzheimer’s disease (AD) patients (Aim 3). Finally, multiple biomarker studies supported by VA and NIH will be corroborated by single-cell proteomic profiling with Helios CyTOF (Aim 4).